# Aging and Hypertension among the Global Poor-Panel Data Evidence from Malawi 

Iliana V. Kohler<br>University of Pennsy/vania, iliana@pop.upenn.edu<br>Nikkil Sudharsanan<br>Technical University of Munich, nikkil.sudharsanan@tum.de<br>Chiwoza Bandawe<br>University of Malawi, cbandawe@gmail.com<br>Hans-Peter Kohler<br>University of Pennsylvania, HPKOHLER@POP.UPENN.EDU

Follow this and additional works at: https://repository.upenn.edu/psc_publications
Part of the Demography, Population, and Ecology Commons, Family, Life Course, and Society Commons, Inequality and Stratification Commons, and the Medicine and Health Commons

## Recommended Citation

Kohler, Iliana, Nikkil Sudharsanan, Chiwoza Bandawe, and Hans-Peter Kohler. 2022. "Aging and Hypertension among the Global Poor-Panel Data Evidence from Malawi." University of Pennsylvania Population Center Working Paper (PSC/PARC), 2022-82. https://repository.upenn.edu/psc_publications/ 82.

# Aging and Hypertension among the Global Poor-Panel Data Evidence from Malawi 


#### Abstract

Background: Hypertension has a rapidly growing disease burden among older persons in low-income countries (LICs) that is often inadequately diagnosed and treated. Yet, most LIC research on hypertension is based on cross-sectional data that does not allow inferences about the onset or persistence of hypertension, its correlates, and changes in hypertension as individuals become older.

Data and methods: The Mature Adults Cohort of the Malawi Longitudinal Study of Families and Health (MLSFH-MAC) is used to provide among the first panel analyses of hypertension for older individuals in a sub-Saharan LIC using blood pressure measurements obtained in 2013 and 2017.

Findings: High blood pressure is very common among mature adults aged 45+ in rural Malawi, and hypertension is more prevalent among older as compared to middle-aged respondents. Yet, in panel analyses for 2013-17, we find no increase in the prevalence of hypertension as individuals become older. Hypertension often persists over time, and the onset of hypertension is predicted by factors such as being overweight/obese, or being in poor physical health. Otherwise, however, hypertension has few socioeconomic predictors. There is also no gender differences in the level, onset or persistence in hypertension. While hypertension is associated with several negative health or socioeconomic consequences in longitudinal analyses, cascade-of-care analyses document significant gaps in the diagnosis and treatment of hypertension.

Conclusions: Our findings indicate that hypertension and related high cardiovascular risks are widespread, persistent, and often not diagnosed or treated in this rural sub-Saharan population of older individuals. Prevalence, onset and persistence of hypertension are common across all subgroupsincluding, importantly, both women and men. While age is an important predictor of hypertension risk, even in middle ages $45-55$ years, hypertension is already widespread. Hypertension among adults aged $45+$ in Malawi is thus more similar to a "generalized epidemic" than in high-income countries where cardiovascular risk has strong socioeconomic gradients and untreated hypertension particularly prevalent in vulnerable subsets of older persons.


## Keywords

hypertension, low-income countries, Mature Adults Cohort of the Malawi Longitudinal Study of Families and Health (MLSFH-MAC), sub-Saharan Africa, rural, cardiovascular risk, Malawi, non-communicable diseases

## Disciplines

Demography, Population, and Ecology | Family, Life Course, and Society | Inequality and Stratification | Medicine and Health | Social and Behavioral Sciences | Sociology

# Aging and Hypertension among the Global Poor-Panel Data Evidence from Malawi 

Iliana V. Kohler*

Nikkil Sudharsanan ${ }^{\dagger}$<br>Hans-Peter Kohler ${ }^{\S}$

Chiwoza Bandawe ${ }^{\ddagger}$

$10^{\text {th }}$ February, 2022

Background: Hypertension has a rapidly growing disease burden among older persons in low-income countries (LICs) that is often inadequately diagnosed and treated. Yet, most LIC research on hypertension is based on cross-sectional data that does not allow inferences about the onset or persistence of hypertension, its correlates, and changes in hypertension as individuals become older.
Data and methods: The Mature Adults Cohort of the Malawi Longitudinal Study of Families and Health (MLSFH-MAC) is used to provide among the first panel analyses of hypertension for older individuals in a sub-Saharan LIC using blood pressure measurements obtained in 2013 and 2017.
Findings: High blood pressure is very common among mature adults aged $45+$ in rural Malawi, and hypertension is more prevalent among older as compared to middle-aged respondents. Yet, in panel analyses for 2013-17, we find no increase in the prevalence of hypertension as individuals become older. Hypertension often persists over time, and the onset of hypertension is predicted by factors such as being overweight/obese, or being in poor physical health. Otherwise, however, hypertension has few socioeconomic predictors. There is also no gender differences in the level, onset or persistence in hypertension. While hypertension is associated with several negative health or socioeconomic consequences in longitudinal analyses, cascade-of-care analyses document significant gaps in the diagnosis and treatment of hypertension.
Conclusions: Our findings indicate that hypertension and related high cardiovascular risks are widespread, persistent, and often not diagnosed or treated in this rural sub-Saharan population of older individuals. Prevalence, onset and persistence of hypertension are common across all subgroups-including, importantly, both women and men. While age is an important predictor of hypertension risk, even in middle ages 45-55 years, hypertension is already widespread. Hypertension among adults aged $45+$ in Malawi is thus more similar to a "generalized epidemic" than in high-income countries where cardiovascular risk has strong socioeconomic gradients and untreated hypertension particularly prevalent in vulnerable subsets of older persons.

[^0]
## 1. Introduction

Hypertension is not only widespread in higher-income countries. To the contrary, levels of hypertension are actually often higher in sub-Saharan African (SSA) and low- and middleincome countries (LMICs) as compared to high-income countries (HICs) (Figure 1A and $[1,2]$ ). Among adults over the age of 18 in SSA as a whole, despite an overall young age structure, more than $20 \%$ of men and women have hypertension (systolic $\mathrm{BP} \geq 140 \mathrm{mmHg}$ or diastolic $\mathrm{BP} \geq 90 \mathrm{mmHg}$ ) [1,2]. The diagnosis and treatment of this widespread hypertension is often inadequate [3]. Moreover, the high prevalence of hypertension in SSA and/or LMIC contrasts with an often low prevalence of "classic" risk factors (i.e., high rates of obesity, unhealthy life styles and reduced physical activity) [1, 2, 4]. In global comparison, for example, women in SSA have among the highest prevalence of hypertension, while they also are among the leanest in the world (Figure 1A+B).

This prevalence and number of individuals in need of hypertension care is expected to grow substantially as LMICs further develop and undergo rapid population aging during the coming decades [1,5-7]. This rise in hypertension is related to a broader shift in the burden of disease in LMICs towards non-communicable diseases (NCDs) that have become leading causes of adult morbidity and mortality in sub-Saharan African (SSA) countries [8]. The shifting disease burden towards NCDs, along with a gradual aging of global populations [9], has been described as a frontier in global health research [10] that is likely to regain focus once the Covid-19 pandemic has receded [7,11].

Figure 1: Prevalence of high blood pressure and obesity by sex across different regions in the world (2015, in \%, age-standardized)


Source: Own calculations based on NCD-RisC [2]. High blood pressure is defined by NCD-RisC as systolic BP $\geq 140 \mathrm{mmHg}$ or diastolic $\mathrm{BP} \geq 90 \mathrm{mmHg}$. Obesity is defined as $\mathrm{BMI} \geq 30$. Prevalence of high blood pressure and obesity are age-standardized so that they are better comparable across countries.

Despite the importance of understanding and addressing hypertension in SSA, an important limitation of existing hypertension research in SSA, and more broadly in lowincome countries (LICs), is that the findings are largely based on cross-sectional data. Importantly, cross-sectional data are not informative about the incidence of hypertension as individuals age, and they cannot differentiate persistent hypertension from temporary episodes of elevated blood pressure. Age-gradients of hypertension observed in crosssectional data can arise from cohort differences, and such age gradients thus may not reflect changes in hypertension prevalence as individuals become older. Hence, if agebased increases in hypertension are used to create thresholds for targeting care efforts, cross-sectional data may misguide clinical decisions. Cross-sectional studies are also limited in their ability to identify the extent to which enhancing awareness and knowledge about blood pressure will improve blood pressure levels over time [12, 13]. Ultimately, only analyses of longitudinal data can provide a better understanding of hypertension as a dynamic process that is interrelated with individual aging and socioeconomic changes. Yet, very few such studies have been conducted in LICs.

Our study is among the first longitudinal analyses of widespread hypertension among aging global poor using panel data from a low-income country. The individuals that we study had lifecourse experiences that are typical for the aging global poor: They lived most of their lives with per capita incomes of less than $\$ 1 /$ day [14]. Fertility was high in these cohorts [15], the status of women was generally low, and income generation through subsistence agriculture and small scale agriculture entailed relatively high levels of physical activity [16]. Older study participants were born when under-5 mortality was almost one out of three [5], and period life expectancies at birth were around 35 years in the 1950s, and remained below 46 years until the early 2000s [5]. All members of our study population have survived sustained poverty, frequent undernutrition, and epidemics. Health at older ages is often poor, and individuals experience accelerated aging with an early onset of morbidity across multiple domains [8, 17-19].

## 2. Methods

Data: Data for this study come from the Mature Adults Cohort of the Malawi Longitudinal Study of Families and Health (MLSFH-MAC), which to our best knowledge is currently the only population-based cohort study of adults in a SSA LICs that collects longitudinal information on blood pressure along with data on hypertension prevalence, incidence, treatment, awareness and knowledge [16, 20]. The MLSFH is based in Malawi, one of the poorest countries in the world that is ranked 174 out of 189 countries in terms of the Human Development Index in $2019\left(\mathrm{HDI}_{2019}=.485\right)$ [21] and has a per-capita GDP equal to about $5 \%$ of the global average [22]. In rural areas, where our study is based and most Malawians ( $85 \%$ ) live, about $60 \%$ of the rural population was considered poor in 2016/17, thus having a total consumption that does not provide 2,400 calories per day per person [23].

The MLSFH-MAC study population consists of adults aged 45+ years living in rural areas in three districts in Malawi (Mchinji, Balaka, Rumphi). Baseline enrollment in 2012 was 1,266 individuals, and the cohort was followed up in 2013, 2017, and 2018, when each time additional eligible MLSFH respondents reaching age 45 years were enrolled in MLSFH-MAC. An MLSFH-MAC Cohort Profile provides detailed information about sampling procedures, study instruments, attrition/follow-up rates [16], and summary statistics for the study population are provided in the Supplemental Materials (Tables S.1-S.2). Life expectancy at birth is currently $\approx 63$ years, and life expectancy at age 45 is currently $\approx 28$ years [5]. Healthy life expectancy at age 45 is estimated around 22 years [8], and older adults can expect to live a large proportion of their later years subject to physical limitations on their activities [24].

We focus on MLSFH-MAC respondents with longitudinal measurements of blood pressure in 2013 (baseline) and the 2017 follow-up. The mean age is about 60 years in 2017, with $37 \%$ of respondents being age $45-54$ years and $14 \%$ age $75+$ years. $60 \%$ of the study population is female, and one quarter is Muslim. The study population is characterized by low levels of formal schooling ( $30 \%$ of respondents have no formal education, and $64 \%$ have only primary education). $58 \%$ of female and $94 \%$ of male respondents were married in 2017, and about half of the respondents resided in a house with a metal/tiled roof. The HIV prevalence for the MLSFH-MAC cohort was $8 \%$ in 2017, with HIV+ individuals concentrated at ages 45-49 years. The majority of respondents ( $66 \%$ ) have body mass index (BMI) that is within the normal range ( $18 \leq \mathrm{BMI} \leq 25$ ) or are underweight $(17 \%$ have BMI below 18). While only a small fraction of the study population is overweight $(12 \%)$ or obese ( $4.7 \%$ ), women are more likely to fall into these high risk BMI categories.
Measurement of blood pressure in MLSFH-MAC: Blood pressure (BP) in MLSFH-MAC was measured in 2013 and 2017 following the protocol developed by the Health and Retirement Study (HRS) [25]. Three BP measurements on the left arm were taken about 1 minute apart in a sitting position in a chair, using an upper arm automated BP monitor (Omron HEM-780N). BP data is available for 1,227 respondents aged 45+ in 2013 and 1,512 in 2017. Longitudinal BP measurements are available for 1,075 MLSFH-MAC participants. Respondents who measured BP above 160 mmHg systolic and/or 110 mmHg diastolic were given a referral for follow up with a doctor or medical professional, but were not provided any other information about blood pressure. Virtually all respondents (e.g., $99 \%$ of participants in 2017) agreed to the BP measurement. Prior to the BP measurement, respondents were asked if they have been diagnosed with hypertension by a doctor or medical personnel in the last two years before the survey, and if they are currently taking medication for reducing BP. Respondents' knowledge about the risks associated with high BP was elicited by asking why it is important for individuals to know their blood pressure, and the importance that respondents attributed to knowing their BP was assessed through a question asking how far (long) they would be willing to walk to a clinic to obtain a (free) BP measurement. Additionally, the 2017 survey included questions on knowledge about

BP and associated risk factors, and a set of questions focused on the ability of respondents to recognize symptoms associated with high BP.
Approach: Individuals are defined as pre-hypertensive if $120 \leq B P_{\text {sys }}<140$ or $80 \leq$ $B P_{\text {dia }}<90$, as hypertensive stage 1 if $140 \leq B P_{\text {sys }}<160$ or $90 \leq B P_{\text {dia }}<100$ and hypertensive stage 2 if $B P_{\text {sys }} \geq 160$ or $B P_{\text {dia }} \geq 100$, where $B P_{\text {sys }}$ denotes systolic and $B P_{\text {dia }}$ diastolic blood pressure. Onset of hypertension is defined as having normal blood pressure or pre-hypertension at baseline (2013), and having Stage 1 or 2 hypertension at follow-up in 2017. In $85 \%$ of cases, systolic BP determines the hypertension classification. Persistent hypertension is defined as being Stage 1 or Stage 2 hypertensive at both baseline (2013) and follow-up (2017). Persistent Stage 2 hypertension is defined as being Stage 2 hypertensive in both 2013 and 2017.

The "cascade of care" concept [26,27] is used to measure linkage to care, health seeking behavior, and effective treatment for individuals with hypertension. The cascade represents the proportion of individuals who reach each separate stage of care, conditional on being included in the previous stage, and it is useful to identify the stages of the disease care cascade where the management of a disease fails. For hypertension care, the following cascade stages are defined: (1) being hypertensive ( $47 \%$ and $46 \%$ of all respondents in 2013 and 2017 respectively), either based on measured BP ( $90 \%$ and $84 \%$ of hypertensive cases in 2013 and 2017 respectively) and / or a reported diagnosis ( $22 \%$ or $39 \%$ of hypertensive cases in 2013 and 2017 respectively); (2) diagnosis of hypertension by a doctor or medical personnel within 2 years prior to the survey; (3) treatment of high BP with medication, and (i) treatment for high BP and controlled BP (= measured BP does not indicate hypertension at time of survey).

We employ standard regression analysis and focus on the results from the longitudinal analyses of hypertension during 2013-17, which are enabled by the longitudinal cohort information available in MLSFH-MAC. Related cross-sectional or complementary results are reported in the Supplemental Materials.
Ethics Approval: This research based on the MLSFH-MAC was approved by the IRB at the University of Protocol \#815016) and the College of Medicine (now Kamuzu University of Health Sciences) in Malawi (COMREC Protocol \#P.01/12/1165).

## 3. Results

Prevalence of hypertension, hypertension incidence and persistent hypertension: At baseline in 2013, $42.5 \%$ of mature adults were hypertensive ( $23.5 \%$ Stage 1, $19 \%$ Stage 2; Table 1). In multivariate analyses, prevalence of hypertension is higher at older ages, is similar between women and men, varies across MLSFH study regions and is not associated with having obtained formal schooling (Supplemental Table S.3).

Hypertension prevalence is similar between the longitudinal sample (Table 1), which is used for our cohort analyses of changes in hypertension 2013-17, and the cross-sectional sample at baseline in 2013, except for a lower prevalence of Stage 1 and Stage 2 hyper-

Table 1: Prevalence of hypertension in 2013, and onset and persistence of hypertension during 2013-17 among MLSFH Mature Adults

|  | Prevalence of Hypertension |  | Change in Hypertension 2013-17 <br> (Longitudinal Sample) |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | Baseline Sample | 2013 <br> Longitud. <br> Sample | Onset Hypertension | Persistent Hypertension | Persistent Stage 2 Hypertens. |
| Normal blood pressure | 25.3\% | 26.0\% | 10.5\% | - | - |
| Pre-hypertension | 32.1\% | 33.0\% | 28.5\% | - | - |
| Stage 1 hypertension | 23.5\% | 23.2\% | - | 59.1\% | - |
| State 2 Hypertension | 19.0\% | 17.8\% | - | 83.1\% | 58.4\% |
| Obs ( $N$ ) | 1,229 | 1,065 |  |  |  |

tension that is due to selective survival (hypertension predicts mortality, but not other attrition, see below).

Cohort analyses show that $10.5 \%$ respondents with normal BP at baseline were hypertensive (Stage 1 or 2) by 2017; this proportion increases to $28.5 \%$ among those who were pre-hypertensive at baseline. $59 \%$ and $83 \%$ of respondents with Stage 1 or Stage 2 hypertension at baseline respectively were still hypertensive (Stage 1 or 2) by $2017.58 \%$ of those with Stage 2 hypertension were still Stage 2 hypertensive by 2017. These patterns of prevalence, onset and persistence of hypertension among adults aged $45+$ are very similar for men and women, and with one exception (onset of hypertension among respondents classified as pre-hypertensive at baseline), not statistically different (Supplemental Table S.4).

Several factors are associated with the onset or persistence of hypertension among adults aged 45+ during 2013-17 (Table 2). There is a weak indication that women are more likely to have an onset of hypertension, but otherwise no clear gender difference in the persistence of hypertension over time. Being overweight or obese increases the odds of hypertension onset and the persistence of hypertension, and poor physical health (low SF12 physical score) and nutritional stress (no consumption of fish or meat in last seven days) predict the onset of hypertension. The same factors also predict changes in systolic BP among respondents not hypertensive at baseline, and in some cases also for the overall study population or other subgroups. Being HIV-positive or Muslim protects against increases in systolic BP. Being married is associated with increases in blood pressure and the persistence of hypertension, contrary to common findings that marriage often found to be protective for cardiovascular health [28]. Notably wealth (various indicators), schooling and grip strength are not predictors of the onset/persistence of hypertension or changes in blood pressure (Supplemental Table S.6).

Blood pressure and aging: Table 3 shows only modest within-person increases in systolic blood pressure during 2013-17: For women aged 45-54 years there is an annual increase in systolic BP of .94 base points per year of age during 2013-17 (similar to the age gradient
Table 2: Predictors of changes in systolic blood pressure, onset and persistence of hypertension

|  | Among 2013 respondents who are |  |  |  |  |  | All respondents <br> Combined |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Not hypertensive |  | Hypertensive Stage 1 or 2 |  | Hypertensive Stage 2 |  |  |  |
|  | Onset of hypertension 2013-17 (Odds Ratio) | $\begin{aligned} & \text { Change in } \\ & \text { systolic } \\ & \text { BP } \\ & \text { 2013-17 } \\ & \text { (OLS Coef) } \end{aligned}$ | Persistence of hypertension 2013-17 (Odds Ratio) | Change in systolic BP 2013-17 (OLS Coef) | Persistence of Stage 2 hypertension 2013-17 (Odds Ratio) | Change in systolic BP 2013-17 (OLS Coef) | Change in systolic BP 2013-17 (OLS Coef) | Change in diastolic BP 2013-17 (OLS Coef) |
| Gender (Ref.: Male) Female | $\begin{gathered} 1.45^{+} \\ {[0.93,2.27]} \end{gathered}$ | $\begin{gathered} 0.99 \\ {[-1.44,3.42]} \end{gathered}$ | $\begin{gathered} 1.28 \\ {[0.86,1.91]} \end{gathered}$ | $\begin{gathered} 1.43 \\ {[-2.19,5.06]} \end{gathered}$ | $\begin{gathered} 1.57 \\ {[0.86,2.85]} \end{gathered}$ | $\begin{gathered} 5.31^{+} \\ {[-0.27,10.9]} \end{gathered}$ | $\begin{gathered} 1.23 \\ {[-0.83,3.28]} \end{gathered}$ | $\begin{gathered} 1.24^{*} \\ {[0.20,2.29]} \end{gathered}$ |
| Body mass index (BMI), Ca Overweight/obese | $\begin{gathered} \hline \text { orical (Ref.: } \\ 2.49^{* *} \\ {[1.55,4.01]} \\ \hline \end{gathered}$ | $\begin{gathered} \text { rmal weight } \\ 4.72^{* *} \\ {[1.31,8.14]} \\ \hline \end{gathered}$ | $\begin{gathered} \hline \text { underweigh } \\ 1.82^{+} \\ {[0.96,3.45]} \\ \hline \end{gathered}$ | $\begin{gathered} 6.61^{* *} \\ {[1.99,11.2]} \end{gathered}$ | $\begin{gathered} 2.88^{* *} \\ {[1.42,5.85]} \end{gathered}$ | $\begin{gathered} 10.0^{*} \\ {[2.28,17.8]} \end{gathered}$ | $\begin{gathered} 4.55^{* *} \\ {[1.40,7.71]} \end{gathered}$ | $\begin{gathered} 0.55 \\ {[-1.06,2.16]} \end{gathered}$ |
| Marital status (Ref.: Not cu Currently married | $\begin{gathered} \hline \text { tly married) } \\ 1.19 \\ {[0.70,2.02]} \\ \hline \end{gathered}$ | $\begin{gathered} 1.49 \\ {[-1.68,4.66]} \end{gathered}$ | $\begin{gathered} 1.88^{*} \\ {[1.06,3.33]} \end{gathered}$ | $\begin{gathered} 6.38^{*} \\ {[1.16,11.6]} \end{gathered}$ | $\begin{gathered} 2.86^{*} \\ {[1.15,7.08]} \end{gathered}$ | $\begin{gathered} 6.55 \\ {[-1.64,14.7]} \end{gathered}$ | $\begin{gathered} 3.74^{*} \\ {[0.70,6.78]} \end{gathered}$ | $\begin{gathered} 1.45^{+} \\ {[-0.031,2.92]} \end{gathered}$ |
| HIV status (Ref.: HIV-negat HIV-positive | $\begin{gathered} 0.24^{+} \\ {[0.054,1.03]} \end{gathered}$ | $\begin{gathered} -5.62^{* *} \\ {[-9.65,-1.58]} \end{gathered}$ | $\begin{gathered} 0.63 \\ {[0.26,1.56]} \end{gathered}$ | $\begin{gathered} -4.04 \\ {[-12.4,4.36]} \end{gathered}$ | $\begin{gathered} 0.2 \\ {[0.019,2.11]} \end{gathered}$ | $\begin{gathered} 4.54 \\ {[-6.85,15.9]} \end{gathered}$ | $\begin{gathered} -4.61^{*} \\ {[-8.82,-0.39]} \end{gathered}$ | $\begin{gathered} -3.79^{* *} \\ {[-6.43,-1.16]} \end{gathered}$ |
| Religion (Ref.: Christian) Muslim <br> Other/none | $\begin{gathered} 0.70 \\ {[0.31,1.59]} \\ 0.73 \\ {[0.25,2.10]} \end{gathered}$ | $\begin{gathered} -5.39^{* *} \\ {[-9.09,-1.69]} \\ 1.30 \\ {[-5.13,7.72]} \end{gathered}$ | $\begin{gathered} 1.02 \\ {[0.47,2.23]} \\ 0.58 \\ {[0.24,1.39]} \end{gathered}$ | $\begin{gathered} -5.59^{*} \\ {[-11.1,-0.065]} \\ -5.50 \\ {[-15.3,4.33]} \end{gathered}$ | $\begin{gathered} 0.67 \\ {[0.29,1.56]} \\ 0.62 \\ {[0.18,2.19]} \end{gathered}$ | $\begin{gathered} -8.34 \\ {[-18.8,2.14]} \\ -4.50 \\ {[-21.5,12.5]} \\ \hline \end{gathered}$ | $\begin{gathered} -5.57^{* *} \\ {[-8.65,-2.50]} \\ -2.07 \\ {[-6.74,2.59]} \end{gathered}$ | $\begin{gathered} -1.25 \\ {[-3.53,1.02]} \\ -0.41 \\ {[-2.95,2.14]} \\ \hline \end{gathered}$ |
| Low protein consumption Ate no fish or meat in last 7 days | $\begin{gathered} \text { : Ate fish or } \\ 2.13^{* *} \\ {[1.36,3.34]} \end{gathered}$ | $\begin{aligned} & \hline \text { eat at least or } \\ & 5.56^{* *} \\ & {[2.42,8.70]} \end{aligned}$ | $\begin{aligned} & \text { in last } 7 \text { day } \\ & 1.01 \\ & {[0.52,1.99]} \end{aligned}$ | $\begin{gathered} 0.055 \\ {[-5.51,5.62]} \end{gathered}$ | $\begin{gathered} 0.55 \\ {[0.24,1.28]} \end{gathered}$ | $\begin{gathered} 1.22 \\ {[-7.05,9.49]} \end{gathered}$ | $\begin{gathered} 3.02^{+} \\ {[-0.29,6.33]} \end{gathered}$ | $\begin{gathered} 2.46^{* *} \\ {[0.72,4.20]} \end{gathered}$ |
| SF12 Physical health score (z SF12 Physical health z-score | $\begin{gathered} \text {-score) } \\ 0.77^{*} \\ {[0.62,0.95]} \\ \hline \end{gathered}$ | $\begin{gathered} -2.34^{* *} \\ {[-4.00,-0.67]} \end{gathered}$ | $\begin{gathered} 1.31^{*} \\ {[1.02,1.68]} \end{gathered}$ | $\begin{gathered} 0.34 \\ {[-2.45,3.14]} \end{gathered}$ | $\begin{gathered} 1.15 \\ {[0.79,1.68]} \end{gathered}$ | $\begin{gathered} -0.47 \\ {[-5.55,4.60]} \end{gathered}$ | $\begin{gathered} -1.48^{+} \\ {[-3.03,0.074]} \end{gathered}$ | $\begin{gathered} -0.65 \\ {[-1.51,0.21]} \end{gathered}$ |
| Observations | $\approx 625$ | $\approx 620$ | $\approx 435$ | $\approx 410$ | $\approx 190$ | $\approx 175$ | $\approx 1030$ | $\approx 1030$ |
| Notes: Tables shows the results of OLS regressions (for change in blood pressure) or logistic regressions (for onset or persistence of hypertension) on the on the predictor variables, controlling additionally for age, gender and region. level. Analyses include all MLSFH-MAC respondents with both 2013 and 2017 BP measurement. Within-person change in BP is calculated as the difference of 2017 BP minus 2013 BP. Outliers in BP change are eliminated as they may reflect measurement errors (outliers are defined as being in the $1^{\text {st }}$ or $99^{\text {th }}$ percentile of the 2013-17 change in BP, $p$-values (robust std. errors): $p<0.10$, * $p<0.05,{ }^{* *} p<0.01$. |  |  |  |  |  |  |  |  |

Table 3: Average annual within-person change in blood pressure during 2013-17, by 2017 age group

|  |  |  |  |  | Pooled <br> Age (2013): |
| :--- | :---: | :---: | :---: | :---: | :---: |
| $\mathbf{4 5 - 5 4}$ | $55-64$ | $\mathbf{6 5 - 7 4}$ | $\mathbf{7 5 +}$ | $\mathbf{4 5 +}$ |  |
| Average annual within-person change in systolic BP: |  |  |  |  |  |
| Women | $0.94^{* *}$ | 0.14 | 0.41 | -0.80 | $0.38+$ |
|  | $[0.45,1.44]$ | $[-0.53,0.81]$ | $[-0.77,1.59]$ | $[-0.77,1.59]$ | $[-0.033,0.79]$ |
| Men | 0.03 | 0.27 | -0.05 | -0.22 | 0.07 |
|  | $[-0.68,0.75]$ | $[-0.50,1.04]$ | $[-1.16,1.05]$ | $[-1.60,1.15]$ | $[-0.77,1.59]$ |


| Average annual within-person change in diastolic BP: |  |  |  |  |  |  |  |  |
| :--- | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Women | -0.14 | $-0.67^{* *}$ | -0.41 | $-0.63^{*}$ | $-0.42^{* *}$ |  |  |  |
|  | $[-0.43,0.14]$ | $[-1.04,-0.30]$ | $[-0.95,0.12]$ | $[-1.24,-0.019]$ | $[-0.62,-0.21]$ |  |  |  |
| Men | $-0.61^{* *}$ | $-0.92^{* *}$ | $-0.76^{* *}$ | -0.53 | $-0.74^{* *}$ |  |  |  |
|  | $[-1.03,-0.20]$ | $[-1.36,-0.48]$ | $[-1.24,-0.28]$ | $[-1.18,0.12]$ | $[-0.97,-0.51]$ |  |  |  |

$p$-values: ${ }^{+} p<0.10,{ }^{*} p<0.05,{ }^{* *} p<0.01 .95 \%$ confidence intervals are estimated based on robust standard errors clustered at the village level. Analyses include all MLSFH-MAC respondents with both 2013 and 2017 BP measurement. Within-person change in BP is calculated as the difference of 2017 BP minus 2013 BP. Outliers in BP change are eliminated as they may reflect measurement errors (outliers are defined as being in the $1^{\text {st }}$ or $99^{\text {th }}$ percentile of the 2013-17 change in BP.
in Western, but more than that in some other low-income populations [29]). There is no systematic age-related increase for men, or women aged 55+. Diastolic blood pressure declines on average as respondents age. Identical conclusions are obtained comparing the adjacent box plots in Figure 2 that show 2013 and 2017 BP among longitudinally followed individuals: there is only minimal change in the distribution of systolic BP as cohort members aged during 2013-17, while diastolic BP declined as the cohort got older.

In combination, Table 3 and Figure 2 indicate that there is no increase in average hypertension risk in the MLSFH-MAC cohort as cohort members aged four years during 2013-17. While hypertension is highly prevalent and often persistent among MLSFH mature adults (Table 1), overall hypertension was not worsening in the MLSFH-MAC cohort: The distribution of hypertension categories in 2017 is indistinguishable from that in 2013 ( $p\left(\chi^{2}\right)=.94$ ) for cohort members who survived and had BP measured at both waves (Table S.5).

Contrasting cohort and cross-sectional patterns in hypertension: In contrast to the relatively "flat" hypertension profile as the cohort got older during 2013-17, there is a strong cross-sectional increase in systolic BP and hypertension with age. For instance, $54.3 \%$ adults aged 45-54 had systolic BP of 120 or higher in 2013, and only $22 \%$ had systolic BP of 140 or higher. At ages $75+$, the respective factions are $78.1 \%$ ( $p<.01$ ) and $52.5 \%(p<.01$ ). The cross-sectional age gradient for systolic BP is . 73 (CI: .95-.87) per year of age in 2013, and . 077 (CI: .0062-.13) for diastolic BP (Table S.3). There is also a corresponding cross-sectional increase in hypertension with age: $30 \%$ of adults aged $45-54$ were hypertensive (Stage 1 or 2 ) in 2013, increasing to $54 \%$ ( $p<.01$ ) at ages $75+$. A 10 year higher age increases the

Figure 2: Systolic blood pressure ( mmHg ) among mature adults in 2013 and 2017, by age in 2013


Notes: Analyses include all MLSFH-MAC respondents with both 2013 and 2017 BP measurement. Age group is assigned based on age in 2013. Systolic BP is top-coded at 200 mmHg . The corresponding graph for diastolic BP is reported in Supplemental Figure S.1. Supplemental Figure S. 2 and Figure S. 3 provide analyses separate for men and women.
odds of being hypertensive in the cross-section by about $42 \%$ (CI: $32-54 \%$ ), with similar increases also pertaining to of stage 2 hypertension (Table S.3). This cross-sectional patterns remains stable in 2017 (Table S.3).

The strong cross-sectional age gradient in BP is in contrast to the flat BP profile documented in our earlier longitudinal analyses (Table 3 and Figure 2). Specifically, this divergence of the BP age-gradient between cohort and cross-sectional analyses is suggestive of potential cohort influences on BP and hypertension, that is, the possibility that the higher BP and hypertension prevalence among older adults is due to higher levels of life-course adversity experience by older persons. Such cohort effects are plausible because worse early-life conditions among older cohorts has been linked to worse health outcomes at older ages (including worse cardiovascular health) [30,31]. This aspect is especially important in countries having experienced socioeconomic development or improvements in health (and thus more pronounced cohort differences in early-life environments) during the 20th century [32, 33]. For example, height, a common indicator of early-life nutritional status that was measured in 2017, declines strongly in our study population with age (agegradient $=-.15 \mathrm{~cm}, p<.01$, with controls for region and gender).
Blood pressure, hypertension prevalence and body mass index: Our earlier analyses have shown that being overweight/obese or having high BMI is a risk factor factor for the onset and persistence of hypertension during 2013-17 (Table 2), as well as for having elevated

Figure 3: Body Mass Index (BMI) of MLSFH-MAC Respondents aged 2012-13


Notes: Based on measured height and weight in 2012 and 2017. Red line denotes the cut-off for obesity ( $\mathrm{BMI} \geq 30$ ), and the blue line denotes the cut-off for overweight ( $25 \leq \mathrm{BMI} \geq 30$ ). Age group is assigned based on age in 2017. Source: Kohler et al. [16]
blood pressure or being hypertensive (Table S.2). Yet, the overall high prevalence of hypertension among MLSFH Mature Adults contrasts sharply with an overall low prevalence of adiposity (Figure 3). Only a small fraction of respondents are overweight ( $12 \%$ of the total sample in 2017), and an even smaller fraction (4.7\%) is obese. Above age 75, where the hypertension prevalence peaks, more than $25 \%$ of the respondents are underweight, and only few are obese ( $2 \%$ ). There is neither a cross-sectional increase of BMI with age, nor a substantive within-person change in BMI during 2012-17. Age-related increases in BMI are not a factor driving the higher prevalence of hypertension at older ages, further confirming that other factors-such as worse early-life conditions or higher levels of life-course adversity-are contributing to the higher levels of hypertension among older persons.
Consequences of being hypertensive: Hypertension predicts mortality in the MLSFHMAC cohort, with hypertensive individuals facing about $60 \%$ higher odds of dying during 2013-18 (Table 4). Importantly for our cohort analyses, hypertension does not predict survey attrition for reasons other than mortality. Among survivors, hypertension at baseline is also associated with several adverse outcomes. For example, hypertension predicts declines in subjective health and SF12 physical health score relative to non-hypertensive cohort members during 2013-17, and it predicts (relative) increases in PHQ9 depression score and GAD7 anxiety scores. There is also evidence that hypertension reduces effort in common moderately-intensive work activities (e.g., time spent in animal care, firewood preparation, planting, etc.) (Table 4). Baseline hypertension does not predict changes in physical health indicators such as grip strength or BMI during 2013-17, nor does it predict

Table 4: Consequences of baseline hypertension in MLSFH-MAC cohort 2013-17

| Hypertension in 2013 (baseline) | Mortality 2013-18 (Odds Ratios) | Nonmortality attrition (Odds Ratios) | 2013-17 Change in: |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | $\begin{aligned} & \text { Subjective } \\ & \text { health } \\ & \text { (OLS Coef.) } \end{aligned}$ | SF12 <br> Physical health score (OLS Coef.) | PHQ9 <br> Depression score (OLS Coef.) |
| Stage 1 Hypertension | $\begin{gathered} 1.24 \\ {[0.78,1.97]} \end{gathered}$ | $\begin{gathered} 1.28 \\ {[0.73,2.23]} \end{gathered}$ | $\begin{gathered} 0.013 \\ {[-0.17,0.20]} \end{gathered}$ | $\begin{gathered} -0.56 \\ {[-1.94,0.82]} \end{gathered}$ | $\begin{gathered} 0.18 \\ {[-0.52,0.88]} \end{gathered}$ |
| Stage 2 Hypertension | $\begin{gathered} 1.89^{* *} \\ {[1.19,2.98]} \end{gathered}$ | $\begin{gathered} 1.03 \\ {[0.60,1.78]} \end{gathered}$ | $\begin{gathered} -0.22^{*} \\ {[-0.40,-0.034]} \end{gathered}$ | $\begin{gathered} -2.51^{* *} \\ {[-4.20,-0.83]} \end{gathered}$ | $\begin{gathered} 1.04^{*} \\ {[0.15,1.94]} \end{gathered}$ |
| Observations | 1,225 | 1,227 | 1,108 | 1,104 | 1,108 |
|  | 2013-17 Change in: |  |  |  |  |
|  | GAD7 <br> Anxiety score (OLS Coef.) | Work efforts (hours/wk) (OLS Coef.) | Grip Strength (OLS Coef.) | Body Mass Index (BMI) (OLS Coef.) | ICA Cognition score (OLS Coef.) |
| Stage 1 Hypertension | $\begin{gathered} 0.32 \\ {[-0.27,0.91]} \end{gathered}$ | $\begin{gathered} -1.57 \\ {[-4.25,1.11]} \end{gathered}$ | $\begin{gathered} -0.18 \\ {[-0.92,0.56]} \end{gathered}$ | $\begin{gathered} -0.025 \\ {[-0.40,0.35]} \end{gathered}$ | $\begin{gathered} \hline 0.13 \\ {[-0.44,0.71]} \end{gathered}$ |
| Stage 2 Hypertension | $\begin{gathered} 0.96^{* *} \\ {[0.30,1.62]} \end{gathered}$ | $\begin{gathered} -6.37^{* *} \\ {[-9.19,-3.55]} \end{gathered}$ | $\begin{gathered} -0.13 \\ {[-0.94,0.68]} \end{gathered}$ | $\begin{gathered} 0.11 \\ {[-0.28,0.50]} \end{gathered}$ | $\begin{gathered} -0.069 \\ {[-0.81,0.68]} \end{gathered}$ |
| Observations | 1,108 | 1,080 | 976 | 1,046 | 1,030 |

changes in cognitive scores.
Awareness of hypertension and knowledge of associated health risks: Respondents attribute significant value to knowing their BP, and around $60 \%$ report in 2013 a willingness to walk up to 1 hour to obtain a BP measurement, and $1 / 3$ reports a willingness to walk more than 2 hours (Table5). These reports are consistent with the almost universal consent to BP measurement as part of our study. This willingness does not increase among respondents who are hypertensive, but it is consistent with respondents associating BP with several dimensions of their overall health. However, not all of these associations are accurate. For instance, about 37\% of respondents in 2013 ( $33 \%$ in 2017) think that knowing one's BP may indicate being HIV-positive (Table 5), an association that is not generally established [34,35]. More than $70 \%$ of baseline respondent correctly state that BP knowledge can be informative about the with risk of stroke, heart disease, and diabetes. About $80 \%$ of respondents think BP is informative about their ability to work and being productive in daily life, in sharp contrast and the mostly asymptomatic nature of high BP (albeit there is some evidence in our study population that stage 2 hypertension leads to reductions in work effort; Table 4). About $46 \%$ of baseline respondents associate BP with malaria, an association that is empirically tenuous [36]. Notably, these assessments about the importance of knowing ones BP do not differ by respondent's own hypertension status: hypertensive

Table 5: Awareness of hypertension and knowledge of the risks associated wih high blood pressure in MLSFH-MAC cohort with 2013 and 2017 blood pressure measurement

|  | Respondent is |  | Combined |
| :---: | :---: | :---: | :---: |
|  | Not hypertensive | Hypertensive |  |
| If a government clinic offering blood pressure measurement were available nearby, would you get your blood pressure measured if you had to walk: |  |  |  |
| 1 hour | 63\% | 59\% | 62\% |
| 2 hours | 45\% | 45\% | 45\% |
| More than 2 hours | 36\% | 34\% | 35\% |
| Why do you think that it might be important for individuals to know their blood pressure? It may tell them... |  |  |  |
| 2013: |  |  |  |
| ...if they have HIV | 37\% | 35\% | 36\% |
| ...about their risk of stroke | 76\% | 70\% | 73\% |
| ...something about how much they can work | 78\% | 79\% | 79\% |
| ...if they have heart problems | 87\% | 88\% | 87\% |
| ...if they have diabetes | 70\% | 74\% | 72\% |
| ...if they have malaria | 45\% | 47\% | 46\% |
| 2017: |  |  |  |
| ...if they have HIV | 33\% | 29\% | 31\% |
| ...about their risk of stroke | 64\% | 65\% | 64\% |
| ...something about how much they can work | 71\% | 74\% | 72\% |
| ...if they have heart problems | 73\% | 77\% | 75\% |
| ...if they have diabetes | 46\% | 44\% | 45\% |
| ...if they have malaria | 34\% | 33\% | 34\% |

individuals do not state more accurate reasons of why it is important to know BP, nor do they give more importance to BP knowledge. At follow-up in 2017, respondents report similar associations of blood pressure with other health outcomes as in 2013, albeit overall there is a declining perception that knowledge about BP can be indicative of other health issues.

Cascade of care for hypertension: There remain substantial gaps in the diagnosis and treatment of hypertension among adults aged 45+ in rural Malawi (Figure 4A). Among all respondents who were identified as hypertensive in 2013, only $22 \%$ have been diagnosed in the last 2 years by a doctor or medical professional as hypertensive (red bar). Among those who were diagnosed, less then 9\% reported in 2013 to be taking treatment for hypertension (green bar); that is for about $61 \%$ of respondents their medical needs for disease treatment were not met in 2013. Among those who were on treatment, only $11 \%$ had BP levels "under control," i.e., within the normal range. The cascade for 2017 among cohort respondents shows an overall improved cascade (Figure 4B), but there remain sub-

Figure 4: Cascade of care for hypertension in rural Malawi, cohort respondents age 45+ yrs. 2013-17


Notes: The cascade represents the proportion of individuals who reach each separate stage of care, conditional on being included in the previous stage. Analyses are based on respondents who participated in both the 2013 and 2017 MLSFH-MAC to ensure that variations in the study populations do not affect the findings; however, similar patterns are identified based on analyses of all 2013 or 2017 respondents.
stantial gaps in care: only $58 \%$ of respondents with measured high levels of BP were not diagnosed in the past as hypertensive, and $54 \%$ of the diagnosed do not report taking treatment. However, only $17 \%$ of hypertensive respondents have attained a measured BP in the normal range. In a related study we have has documented that prior testing-and specifically the receipt of referral letters to health care providers-helped reduce blood pressure, increase diagnoses and update of medication [12] (similar findings have also been shown in South Africa [13]). The blood pressure screening that was conducted as part of the MLSFH-MAC may therefore have been instrumental in achieving improvements in case between 2013 and 2017 (Figure 4A+B).

## 4. Summary and Discussion

Cardiovascular diseases (CVDs) are rapidly becoming a major source of morbidity and mortality in many Sub-Saharan African (SSA) countries, while disease burdens attributable to communicable diseases are decreasing [8]. Addressing the implications of this shifting disease burden, which occurs together with a rapid aging of SSA populations, is critical for achieving the "grand convergence" in health that has been proposed as an achievable global health goal by 2035 [37]. Importantly, a renewed focus on NCDs-including hypertension as a top priority-will be critical as the Covid-19 pandemic has further revealed the incredible challenges of addressing a dual burden of communicable and noncommunicable diseases in LICs [38], as well as the health and social vulnerabilities in LIC population that are caused by an often inadequately treated burden of noncommunicable diseases [39].

The rural subsistence agriculture population that is the focus of this study has low
levels of modernization, very limited exposure to "classic" risk factors such as fast food consumption/unhealthy life styles, and is characterized by high levels of physical activity. Hypertension in such low-income populations has rarely been investigated using longitudinal data, and this is especially the case for older persons who are most at risk of cardiovascular diseases. Drawing on MLSFH-MAC panel data, this study is able to fill an important niche in the literature by highlighting cohort patterns of hypertension and highlighting the dynamics of onset and persistence of hypertension as individuals age during 2013-17.

Key findings of our analyses of blood pressure in this aging poor SSA population pertain to several domains of hypertension research: (1) Prevalence of hypertension and its predictors: Hypertension is highly prevalent among individuals aged $45+$, with more than $40 \%$ being hypertensive and more than $30 \%$ being pre-hypertensive. These high rates of hypertension affect both men and women age 45+, in contrast to strong gender differences that have been documented in higher-income populations (Figure 1A). In our study population, the prevalence of hypertension is much higher than that of being overweight or obese, and while being overweight/obese is a predictor of hypertension, the higher prevalence of hypertension at older ages is not associated with higher levels of adiposity at older ages.
(2) Hypertension and aging-longitudinal changes in blood pressure: (a) While there is a strong cross-sectional age gradients in blood pressure and hypertension, with older individuals having worse cardiovascular health, our longitudinal analyses using MLSFHMAC data 2013-17 that on average a relatively flat profile of blood pressure or hypertension. As cohort members aged during 2012-17, there is no discernible increase in average blood pressure or the prevalence of hypertension: among longitudinally followed MLSFHMAC respondents, the distribution of hypertension categories in 2017 is indistinguishable from that in 2013. The aging of the cohort during 2013-17 did therefore not increase average blood-pressure-related cardiovascular risk in this poor study population. (b) This divergence of cross-sectional and longitudinal age-gradient in BP and hypertension is likely due to cohort influences: earlier cohorts had worse early-life environments that, consistent with the Barker hypotheses [40], translated into worse cardiovascular health at older ages. (c) Despite the relatively stable distribution of blood pressure as the MLSFH-MAC cohort aged during 2021-17, blood-pressure-related cardiovascular risk is dynamic on the individual level. Among respondents with normal BP in 2013, about $10 \%$ experienced an onset of hypertension by 2017; among pre-hypertensive respondents in 2013, this rate almost triples and $28.5 \%$ experienced an onset of hypertension. (d) Stage 1 or 2 Hypertension, however, are often persistent: 59\% of respondents with Stage 1 hypertension in 2013 were still hypertensive in 2017, and this is the case for $84 \%$ of respondents with Stage 2 hypertension at baseline in 2013. (e) The overall stable hypertension profile in the MLSFH-MAC cohort during 2013-17 arises because the onset of hypertension is compensated by who experience a decline in blood pressure or a transition from being hypertensive to normal blood pressure or pre-hypertension.
(3) Predictors of onset of hypertension over time: (a) Being overweight/obese is a strong predictor of the onset and persistence of hypertension during 2012-17, and poor physical health (low S12 physical score) and facing nutritional stress (not having eaten fish or meat in last 7 days at baseline) predicts the onset of hypertension. Being HIV-positive or Muslim implies lower odds of experiencing increases in systolic BP. Interestingly, marriage may not be protective for cardiovascular health, in contrast to a common finding in other populations [28]. Being currently married in our study population is associated with increasing blood pressure over time and the persistence of hypertension. (b) Nevertheless, there are few systematic socioeconomic predictors of the onset or persistence of hypertension in this study population aged 45+ during 2013-17; notably neither schooling, wealth, nor grip strength (all measured in 2013) predict the onset/persistence of hypertension during 2013-17 or changes in systolic/diastolic blood pressure (albeit these factors predict crosssectional level differences in BP or hypertension prevalence in the expected direction).
(4) Life-course conseuqences of hypertension: Importantly, hypertension is has measurable consequences among adults aged $45+$ in Malawi. Hypertension for example predicts mortality in the MLSFH-MAC population during 2013-17, with hypertensive individuals facing about $60 \%$ higher odds of dying. Yet, hypertension is not associated with nonmortality attrition in the MLSFH-MAC. Hypertension at baseline also associated with declines in subjective health, SF12 physical health scores and work efforts during 2013-17 and it is associated with increases in depression and anxiety. These findings thus reaffirm that hypertension is an important public health concern among adults aged 45+ in rural Malawi that is associated with more rapid declines in health as individuals get older.
(5) Cascade of hypertension care: While diagnoses and treatment of hypertension are improving, our analyses of the cascade of care document that there remain substantial gaps in the diagnosis and treatment of hypertension among adults aged 45+ in rural Malawi. In 2013, for example, only $22 \%$ have been diagnosed in the last two years by a doctor or medical professional as hypertensive, and among those who were diagnosed, less then $9 \%$ reported in 2013 to be taking treatment for hypertension. Yet, this cascade of care substantially improved by 2017. $43 \%$ of hypertensive individuals were diagnosed, and $46 \%$ of the diagnosed were taking treatments. Yet, despite these improvements in the cascade of care, only $17 \%$ of hypertensive respondents have attained a measured BP in the normal range. These gaps in the cascade of care are disconcerting as high blood pressure is one of the main modifiable causes of cardiovascular disease risk with a large body of evidence showing that lowering blood pressure through low-cost and widely available medications significantly reduces CVD mortality [41].

Overall, our findings in this paper indicate that hypertension and related high cardiovascular risks are widespread, persistent and often not diagnosed or treated in this rural sub-Saharan population aged 45+. The prevalence, onset and persistence of hypertension cuts across all subgroups in this population-including, importantly, both women and men. While age is an important predictor of hypertension risk, as has been documented in other LMIC contexts [7], hypertension is already widespread in in middle ages
$45-55$ years. Hence, hypertension among adults $45+$ in Malawi seems to be more similar to a "generalized epidemic" than in high-income countries where cardiovascular risk has strong socioeconomic gradients and untreated hypertension particularly prevalent in vulnerable subsets of older persons [42].

Yet, our findings do not provide a bleak picture about hypertension and cardiovascular disease risk in poor aging populations in SSA or elsewhere. In contrast, a recent body of research has started to provide evidence that relatively inexpensive screenings and referrals for hypertension and are effective approach to reduce the gaps in the cascade of care for hypertension $[12,13]$. Our findings highlight the urgency of building on this recent evidence and expand information about cardiovascular risk, screening for hypertension and available treatments for elevated blood pressure to the global poor. Such efforts are likely to have large returns in terms of improving population health among older persons [37].

Some limitations of our study are noteworthy. While the MLSFH-MAC is based on a large, population-based sample of adults $45+$ years old living in a rural SSA LIC context, it is not a nationally representative sample. This concern is somewhat ameliorated by the fact that the MLSFH-MAC cohort characteristics closely match that of cross-sectional nationally-representative samples [16] and the fact that roughly $85 \%$ of the Malawian population resides in rural areas [43]. Hence, our findings can likely be generalized to other rural areas in Malawi and similar low-income populations in southeastern SSA. The age range covered in our study (age 45+ years) is also comparable to other aging studies in SSA LICs [44], and given life expectancy trends in Malawi and SSA more generally, the study represents adequately the experience of the older population in the region. As in any longitudinal study, attrition is a concern for the MLSFH. However, non-mortalityrelated attrition has been very low in the MLSFH-MAC as a result of migration tracking and related fieldwork procedures; during 2012-18 the MLSFH-MAC retained $97 \%$ of surviving respondents [16]; importantly, non-mortality-related attrition 2013-17 is not associated with hypertension. Detailed analyses of attrition as part of the MLSFH cohort profiles $[16,20]$ have also shown that, even though respondent characteristics often differ significantly between those who were lost to follow-up and those who were re-interviewed, the coefficient estimates for standard family background variables in regressions and probit equations for many health outcomes are not significantly affected by attrition.

Population-based blood pressure measurement in rural older and poor populations in challenging, and measurements of blood pressure on a single session-as is conducted in most population-based health surveys, including the MLSFH-does not provide a clinical diagnoses of hypertension. Yet the MLSFH-MAC adopted the protocol for Health and Retirement Study [25], and through extensive training and carefully-developed fieldwork logistics, the MLSFH-MAC not only achieved very high rates of consent to blood pressure measurements, and data quality of the blood pressure measures is generally high [16]. However, the MLSFH-MAC data lack details about how individuals are affected by hypertension, and among those who are treatment, what specific type of hypertension they receive and / or how frequently they are followed up by the health system.

Given the scarcity of longitudinal data on blood pressure and hypertension in SSA lowincome populations, the limitations of this study are relatively minor. The MLSFH-MAC is one of the rare cohort studies in a SSA LICs that provides detailed longitudinal information about blood pressure, hypertension knowledge and treatment, and our analyses are among the first that document the cohort patterns of hypertension in an aging SSA LIC population.

## 5. Acknowledgments

We gratefully acknowledge the generous support for the Malawi Longitudinal Study of Families and Health (MLSFH) by the Rockefeller Foundation; the National Institute of Child Health and Human Development (NICHD, Grant\# R01 HD053781, R01 HD087391); the National Institute on Aging (NIA, Grant\# P30 AG12836 and R21 AG053763); the Boettner Center for Pensions and Retirement Security at the University of Pennsylvania; and the NICHD Population Research Infrastructure Program (Grant\# R24 HD-044964), all at the University of Pennsylvania. We are also grateful for support through the Swiss Programme for Research on Global Issues for Development (SNF r4d Grant 400640-160374) as well as pilot funding received through the Penn Center for AIDS Research (CFAR), supported by NIAID AI 045008 and the Penn Institute on Aging.

## 6. Literature Cited

[1] NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet 2021; 398(10304):957-980.
[2] NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: A pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet 2017; 389(10064):37-55. http://www.ncdrisc. org/.
[3] Geldsetzer P, et al. The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1.1 million adults. Lancet 2019; 394(10199):652-662.
[4] The Economist. Daily chart: The curious case of high blood pressure around the world. Economist 2017; January 13, 2017. http://www.economist.com/blogs/graphicdetail/ 2017/01/daily-chart-12.
[5] UN Population Division. World Population Prospects, the 2019 revision, 2019. United Nations, Department of Economic and Social Affairs, Population Division. https:// population.un.org/wpp/.
[6] Sudharsanan N, Geldsetzer P. Impact of coming demographic changes on the number of adults in need of care for hypertension in Brazil, China, India, Indonesia, Mexico, and South Africa. Hypertension 2019; 73(4):770-776.
[7] Kirschbaum TK, Theilmann M, Sudharsanan N, Manne-Goehler J, Lemp JM, De Neve JW, et al. Targeting hypertension screening in low- and middle-income countries: A cross-sectional analysis of 1.2 million adults in 56 countries. Journal of the American Heart Association 2021; 10(13):e021063.
[8] GBD 2019 Disease Collaboration. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020; 396(10258):1204-1222.
[9] Kämpfen F, Wijemunige N, Evangelista B. Aging, non-communicable diseases, and old-age disability in low- and middle-income countries: a challenge for global health. International Journal of Public Health 2018; 63(9):1011-1012.
[10] Greenberg H, Raymond SU, Leeder SR. The prevention of global chronic disease: Academic public health's new frontier. American Journal of Public Health 2011; 101(8):13861390.
[11] Herrick C, Reubi D. The future of the global noncommunicable disease agenda after Covid-19. Health \& Place 2021; 71:102672.
[12] Ciancio A, Kämpfen F, Kohler HP, Kohler IV. Health screening for emerging disease burdens among the global poor: Evidence from Sub-Saharan Africa. Journal of Health Economics 2021; 75. Available online 9 November 2020.
[13] Sudharsanan N, Chen S, Garber M, Bärnighausen T, Geldsetzer P. The effect of homebased hypertension screening on blood pressure change over time in South Africa. Health Affairs 2020; 39(1):124-132.
[14] Malawi NSO. Malawi Poverty Report 2018. Lilongwe, Malawi: Government of Malawi, National Statistical Office (NSO), 2018. http://www.nsomalawi.mw/images/stories/ data_on_line/economics/poverty/Malawi $\backslash$ \%20Poverty $\backslash \% 20$ Report $\backslash \% 20-\backslash \% 202019 \backslash$ \%20.pdf.
[15] Kohler IV, Kohler HP, Anglewicz P, Behrman JR. Intergenerational transfers in the era of HIV/AIDS: Evidence from rural Malawi. Demographic Research 2012; 27(27):775834.
[16] Kohler IV, Bandawe C, Ciancio A, Kämpfen F, Payne C, Mwera J, et al. Cohort profile: The Mature Adults Cohort of the Malawi Longitudinal Study of Families and Health (MLSFH-MAC). BMJ Open 2020; 10:e038232.
[17] Koyanagi A, Lara E, Stubbs B, Carvalho AF, Oh H, Stickley A, et al. Chronic physical conditions, multimorbidity, and mild cognitive impairment in low- and middleincome countries. Journal of the American Geriatrics Society 2018; 66(4):721-727.
[18] Bollyky TJ, Templin T, Cohen M, Dieleman JL. Lower-income countries that face the most rapid shift in noncommunicable disease burden are also the least prepared. Health Affairs 2017; 36(11):1866-1875.
[19] WHO. World Report on Ageing and Health. Geneva, Switzerland: World Health Organization (WHO), 2015. http://www.who.int/ageing/publications/world-report-2015/ en/.
[20] Kohler HP, Watkins SC, Behrman JR, Anglewicz P, Kohler IV, Thornton RL, et al. Cohort profile: The Malawi Longitudinal Study of Families and Health (MLSFH). International Journal of Epidemiology 2015; 44(2):394-404.
[21] UNDP. Human development report 2020: Briefing notes for Malawi, 2020. United Nations Development Programme (UNDP). http://hdr.undp.org/sites/all/themes/ hdr_theme/country-notes/MWI.pdf.
[22] Bank W. World Bank Open Data: GNI per capita, Atlas method (current US\$), 2020. https://data.worldbank.org/indicator/NY.GNP.PCAP.CD?locations=MW-1W\& view=chart.
[23] Malawi NSO. Preliminary report: 2018 malawi population and housing census: Be counted. leave no one behind, 2018. Malawi National Statistical Office, Zomba, Malawi, December 2018.
[24] Payne C, Mkandawire J, Kohler HP. Disability transitions and health expectancies among adults 45 years and older mature in Malawi: A cohort modeling approach. PLOS Medicine 2013; 10(5):e1001435.
[25] Health and Retirement Study (HRS). HRS 2010 Study Materials (CD for training interviewers and data collectors), 2010. University of Michigan.
[26] Stokes A, Berry K, Mchiza Z, Parker W, Labadarios D, Chola L, et al. Prevalence and unmet need for diabetes care across the care continuum in a national sample of south african adults: Evidence from the sanhanes-1, 2011-2012. PL 2017; 12(10):e0184264.
[27] MK A, K B, EW G, del Rio C. A cascade of care for diabetes in the united states: Visualizing the gaps. Annals of Internal Medicine 2014; 161(10):681-689. +http:/ /dx. doi.org/10.7326/M14-0019.
[28] Wong CW, Kwok CS, Narain A, Gulati M, Mihalidou AS, Wu P, et al. Marital status and risk of cardiovascular diseases: a systematic review and meta-analysis. Heart 2018; 104(23):1937.
[29] Gurven M, Blackwell AD, Rodriguez DE, Stieglitz J, Kaplan H. Does blood pressure inevitably rise with age? Hypertension 2012; 60(1):25-33.
[30] Barker DJP. Fetal origins of coronary heart disease. British Medical Journal 1995; 311(6998):171.
[31] Hoffman DJ, Reynolds RM, Hardy DB. Developmental origins of health and disease: current knowledge and potential mechanisms. Nutritrion Reviews 2017; 75(12):951970.
[32] Engle PL, Black MM, Behrman JR, de Mello MC, Gertler, Kapiriri L, et al. Strategies to avoid the loss of developmental potential in more than 200 million children in the developing world. Lancet 2007; 369(9557):229-242.
[33] Grantham-McGregor S, Cheung YB, Cueto S, Glewwe P, Richter L, Strupp B. Developmental potential in the first 5 years for children in developing countries. Lancet 2007; 369(9555):60-70.
[34] Jericó C, Knobel H, Montero M, Sorli ML, Guelar A, Gimeno JL, et al. Hypertension in

HIV-infected patients: Prevalence and related factors. Amerian Journal of Hypertension 2005; 18(11):1396-1401.
[35] Dillon DG, Gurdasani D, Riha J, Ekoru K, Asiki G, Mayanja BN, et al. Association of HIV and ART with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysis. International Journal of Epidemiology 2014; 42(6):1754-1771.
[36] Eze IC, Bassa FK, Essé C, Koné S, Acka F, Laubhouet-Koffi V, et al. Epidemiological links between malaria parasitaemia and hypertension: findings from a populationbased survey in rural Côte d'Ivoire. Journal of Hypertension 2019; 37(7):1384-1392.
[37] Jamison DT, Summers LH, Alleyne G, Arrow KJ, Berkley S, Binagwaho A, et al. Global health 2035: A world converging within a generation. Lancet 2013; 382(9908):18981955.
[38] Collins T, Tello J, Van Hilten M, Mahy L, Banatvala N, Fones G, et al. Addressing the double burden of the COVID-19 and noncommunicable disease pandemics: a new global governance challenge. International Journal of Health Governance 2021; 26(2):199212.
[39] WHO. The impact of the COVID-19 pandemic on noncommunicable disease resources and services: results of a rapid assessment. Geneva, Switzerland: World Health Organization WHO, 2020. https://www.who.int/teams/noncommunicable-diseases/covid-19.
[40] Barker D, Eriksson J, Forsen T, Osmond C. Fetal origins of adult disease: strength of effects and biological basis. International Journal of Epidemiology 2002; 31:1235-1239.
[41] GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392(10159):1923-1994.
[42] Leng B, Jin Y, Li G, Chen L, Jin N. Socioeconomic status and hypertension: a metaanalysis. Journal of Hypertension 2015; 33(2):221-229.
[43] Malawi NSO. 2018 Malawi Population and Housing Census: Main Report. Zomba, Malawi,: Malawi National Statistical Office (Malawi NSO), 2019. http://www.nsomalawi.mw/images/stories/data_on_line/demography/ census_2018/2018 <br>%20Malawi $\backslash$ \%20Population $\backslash \% 20$ and $\backslash \% 20 H o u s i n g ~ \ \% 20 C e n s u s ~ \ ~$ \%20Main <br>%20Report.pdf.
[44] Brinkmann B, Payne CF, Kohler I, Harling G, Davies J, Witham M, et al. Depressive symptoms and cardiovascular disease: a population-based study of older adults in rural Burkina Faso. BMJ Open 2020; 10(12):e038199.

## Supplemental Materials <br> Additional Figures

Figure S.1: Diastolic blood pressure ( $\mathbf{m m H g}$ ) among mature adults in 2013 and 2017, by age in 2013


Figure S.2: Systolic blood pressure (BP mmHg) among mature adults in 2013 and 2017, by gender and age in 2013


Notes: Analyses include all MLSFH-MAC respondents with both 2013 and 2017 BP measurement. Age group is assigned based on age in 2013. Systolic BP is top-coded at 200 mmHg .

Figure S.3: Diastolic blood pressure (BP mmHg) among mature adults in 2013 and 2017, by gender and age in 2013


Notes: Analyses include all MLSFH-MAC respondents with both 2013 and 2017 BP measurement. Age group is assigned based on age in 2013. Diastolic BP is top-coded at 110 mmHg .

## Additional Tables

Table S.1: Summary statistics for the MLSFH Mature Adult Cohort in 2017 (respondents with BP measurement), and bivariate associations with systolic and diastolic blood pressure

| 2017 MLSFH Mature Adults |  |  |  |  |  |
| :--- | ---: | ---: | ---: | ---: | ---: |
|  |  |  |  |  | Bivariate association <br> with blood pressure |
|  | Women | Men | Total | Systolic | Diastolic |
| \# of observations | 910 | 602 | 1,512 |  |  |
| Age | 60.4 | 60.9 | 60.6 |  |  |
|  | $(11.9)$ | $(11.5)$ | $(11.7)$ |  |  |
| Age Group |  |  |  |  |  |
| 45-54 | 0.38 | 0.36 | 0.37 | Ref. | Ref. |
| 55-64 | 0.30 | 0.28 | 0.29 | $7.73^{* *}$ | 1.04 |
| 65-74 | 0.18 | 0.21 | 0.19 | $14.4^{* *}$ | $1.99^{*}$ |
| 75+ | 0.14 | 0.15 | 0.14 | $19.8^{* *}$ | 1.53 |
| Schooling attainment |  |  |  |  |  |
| No formal schooling | 0.37 | 0.19 | 0.30 | Ref. | Ref. |
| Primary schooling | 0.60 | 0.70 | 0.64 | $-5.27^{* *}$ | -1.14 |
| Secondary or higher | 0.03 | 0.12 | 0.06 | -3.56 | 0.58 |
| Muslim | 0.26 | 0.23 | 0.25 | $4.15^{* *}$ | $1.56^{*}$ |
| Currently married | 0.58 | 0.94 | 0.72 | -2.32 | -0.18 |
| Wealth indicator: House has metal/tiled roof | 0.48 | 0.51 | 0.49 | $2.46^{+}$ | 0.96 |
| Respondent is female | - | - | 0.60 | -0.98 | 0.97 |
| Region |  |  |  |  |  |
| $\quad$ Mchinji | 0.30 | 0.37 | 0.33 | Ref. | Ref. |
| Balaka | 0.36 | 0.29 | 0.34 | $5.88^{* *}$ | $1.92^{*}$ |
| Rumphi | 0.34 | 0.34 | 0.34 | -0.51 | 0.14 |

Notes: Bivariate associations in Columns 4-5 are estimated by regressing systolic or diastolic blood pressure individually on age (linear), age group (categorical), schooling attainment, being muslim, being currently married, having a metal roof and being female. $p$-values (robust std. errors): $p<0.10,{ }^{*} p<0.05$, ${ }^{* *} p<0.01$.

Table S.2: Health indicators for the MLSFH Mature Adult Cohort in 2017 (respondents with BP measurement), and associations with systolic and diastolic blood pressur

| 2017 MLSFH Mature Adults | Women | Men | Total | Association with blood pressure |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  |  |
|  |  |  |  | Systolic | Diastolic |
| \# of observations | 910 | 602 | 1512 |  |  |
| Systolic blood pressure | 132.9 | 133.8 | 133.3 |  |  |
| (mean of 3 measurements) | (25.4) | (22.9) | (24.5) |  |  |
| Diastolic blood pressure | 84.0 | 83.0 | 83.6 |  |  |
| (mean of 3 measurements) | (12.9) | (11.8) | (12.5) |  |  |
| Body Mass Index |  |  |  |  |  |
| Underweight ( $B M I<18.5$ ) | 0.16 | 0.18 | 0.17 | Ref. | Ref. |
| Normal ( $18.5 \leq B M I<25)$ | 0.62 | 0.73 | 0.66 | 0.76 | -0.040 |
| Overweight ( $25 \leq B M I<30$ ) | 0.15 | 0.079 | 0.12 | 8.38** | 4.50 ** |
| Obese ( $\mathrm{BMI} \geq 30$ ) | 0.068 | 0.015 | 0.047 | $12.4 * *$ | 7.88** |
| Grip strength (average both hands) | 19.8 | 27.0 | 22.7 | 0.33** | 0.17** |
|  | (5.24) | (6.35) | (6.71) |  |  |
| Subjective health |  |  |  |  |  |
| very poor | 0.078 | 0.058 | 0.070 | Ref. | Ref. |
| poor | 0.26 | 0.18 | 0.23 | -0.39 | -0.080 |
| good | 0.44 | 0.44 | 0.44 | -3.06 | -1.02 |
| very good | 0.17 | 0.26 | 0.21 | -2.84 | -1.26 |
| excellent | 0.056 | 0.062 | 0.058 | -5.61 | -1.91 |
| Subjective well-being |  |  |  |  |  |
| Very unsatisfied | 0.013 | 0.017 | 0.015 | Ref. | Ref. |
| Somwhat unsatisfied | 0.13 | 0.12 | 0.13 | 2.50 | 1.54 |
| Satisfied | 0.34 | 0.25 | 0.30 | 1.38 | 1.18 |
| Somwhat satisfied | 0.31 | 0.33 | 0.32 | 0.65 | 0.26 |
| Very satisfied | 0.20 | 0.28 | 0.24 | -0.021 | 0.24 |
| Ill in past 12 months |  |  |  |  |  |
| No illness | 0.30 | 0.41 | 0.34 | Ref. | Ref. |
| Ill for < 1 month | 0.53 | 0.47 | 0.51 | 1.04 | -0.041 |
| Ill for 1-3 months | 0.12 | 0.076 | 0.10 | -0.64 | -0.81 |
| Ill for $>3$ months | 0.051 | 0.047 | 0.049 | 0.71 | -0.98 |
| HIV positive | 0.082 | 0.080 | 0.082 | -8.73** | -4.16** |

Notes: Associations in Columns 4-5 are estimated by regressing systolic or diastolic blood pressure individually body mass index, grip strength, subjective health, subjective well-being, illness and HIV status, controlling for age, gender and MLSFH study region. $p$-values (robust std. errors): $p<0.10$, * $p<0.05$, $^{* *} p<0.01$.

Table S.3: Cross-sectional association of blood pressure and hypertension with age, 2013 and 2017

|  | Blood Pressure |  | Stage 1 or 2 <br> Hypertension (Odds Ratio) | Stage 2 <br> Hypertension (Odds Ratio) |
| :---: | :---: | :---: | :---: | :---: |
|  | Systolic (OLS Coef) | Diastolic (OLS Coef) |  |  |
| 2013 (Cross section, no controls) |  |  |  |  |
| Age | 0.73** | 0.077* | 1.04** | 1.04** |
|  | [0.59,0.87] | [0.0070,0.15] | [1.03,1.05] | [1.03,1.06] |
| Observations | 1227 | 1227 | 1227 | 1227 |
| 2013 (Cross section, basic controls) |  |  |  |  |
| Age | 0.70** | 0.070* | 1.04** | 1.04** |
|  | [0.57,0.84] | [0.0005,0.14] | [1.03,1.05] | [1.03,1.06] |
| Any schooling | -0.25 | -0.007 | 0.98 | 0.94 |
|  | [-3.75,3.25] | [-1.80,1.78] | [0.73,1.32] | [0.66,1.35] |
| Female | 0.51 | 0.74 | 0.96 | 1.23 |
|  | [-2.83,3.85] | [-1.01,2.48] | [0.71,1.31] | [0.88,1.73] |
| Region (Ref.: Mchinji) [0, |  |  |  |  |
| Balaka | 4.50* | 1.06 | 1.36* | 1.06 |
|  | [0.13,8.87] | [-0.92,3.03] | [1.02,1.82] | [0.71,1.57] |
| Rumphi | -5.89** | $-2.06{ }^{+}$ | 0.69* | 0.51** |
|  | [-10.0,-1.74] | [-4.31,0.19] | [0.49,0.97] | [0.34,0.76] |
| Observations | 1226 | 1226 | 1226 | 1226 |
| 2017 (Cross section, no controls) |  |  |  |  |
| Age | 0.71** | 0.087** | 1.05** | 1.05** |
|  | [0.58,0.83] | [0.026,0.15] | [1.04,1.06] | [1.03,1.06] |
| Observations | 1512 | 1512 | 1512 | 1512 |
| 2017 (Cross section, basic controls) |  |  |  |  |
| Age | 0.68** | 0.082** | 1.05** | 1.05** |
|  | [0.57,0.80] | [0.025,0.14] | [1.04,1.06] | [1.03,1.06] |
| Any schooling | -0.65 | 0.45 | 0.85 | 0.99 |
|  | [-3.74,2.43] | [-1.17,2.08] | [0.66,1.10] | [0.72,1.37] |
| Female | -0.87 | 1.06 | 0.99 | 1.03 |
|  | [-3.47,1.73] | [-0.27,2.39] | [0.77,1.28] | [0.74,1.44] |
| Region (Ref.: Mchinji) |  |  |  |  |
| Balaka | 4.88** | 1.91* | 1.19 | 1.24 |
|  | [1.52,8.24] | [0.098,3.72] | [0.90,1.58] | [0.86,1.78] |
| Rumphi | 0.19 | -0.033 | 1.06 | 0.89 |
|  | [-2.62,3.00] | [-1.75,1.69] | [0.81,1.37] | [0.60,1.31] |
| Observations | 1506 | 1506 | 1506 | 1506 |

Notes: OLS regression or logistic regression of 2013 or 2017 hypertension on the covariates included in the table. $p$-values (robust std. errors): ${ }^{+} p<0.10,{ }^{*} p<0.05,{ }^{* *} p<0.01$.

Table S.4: Prevalence of hypertension in 2013, by gender, and onset and persistence of hypertension during 2013-17, by gender

|  | Prevalence of <br> Hypertension |  |  | Change in Hypertension 2013-17 <br> (Longitudinal Sample) |  |  |
| :--- | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 2013 <br> Baseline <br> Sample | Longitud. <br> Sample |  | Onset <br> Hyper- <br> tension | Persistent <br> Hyper- <br> tension | Persistent <br> Stage 2 <br> Hypertens. |
| Women |  |  |  |  |  |  |
| Normal blood pressure | $26.5 \%^{n s}$ | $27.0 \%^{n s}$ |  | $9.4 \%^{n s}$ | - | - |
| Pre-hypertension | $31.4 \%^{n s}$ | $32.4 \%^{n s}$ |  | $34.1 \%^{* *}$ | - | - |
| Stage 1 hypertension | $21.8 \%^{n s}$ | $22.0 \%^{n s}$ |  | - | $59.7 \%^{n s}$ | - |
| State 2 Hypertension | $20.3 \%^{n s}$ | $18.6 \%^{n s}$ |  |  |  |  |

$p$-values for test for equality between women and men: ${ }^{+} p<0.10,{ }^{*} p<0.05,{ }^{* *} p<0.01,{ }^{n s}$ difference not statistically different at $10 \%$.

Table S.5: Prevalence of hypertension in 2013 and 2017 among MLSFH Mature Adults with blood pressure measurement in both years

|  | Year |  |  |
| :--- | ---: | ---: | ---: |
|  | $\mathbf{2 0 1 3}$ | $\mathbf{2 0 1 7}$ | Combined |
| Normal blood pressure | $26.0 \%$ | $25.3 \%$ | $25.6 \%$ |
| Pre-hypertension | $33.0 \%$ | $34.1 \%$ | $33.5 \%$ |
| Stage 1 hypertension | $23.2 \%$ | $23.3 \%$ | $23.2 \%$ |
| State 2 hypertension | $17.8 \%$ | $17.4 \%$ | $17.6 \%$ |
| Observations $(N)$ | 1,065 | 1,065 |  |
| Pearson $\chi^{2}(3)=0.39, p$-value $=0.94$ |  |  |  |

Table S.6: Predictors of changes in systolic blood pressure, onset and persistence of hypertension (additional findings)

|  | Among 2013 respondents who are |  |  |  |  |  | All respondents Combined |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Not hypertensive |  | Hypertensive Stage 1 or 2 |  | Hypertensive Stage 2 |  |  |  |
|  | Onset of hypertension 2013-17 <br> (Odds Ratio) | Change in systolic BP 2013-17 (OLS Coef) | Persistence of hypertension 2013-17 (Odds Ratio) | Change in systolic BP 2013-17 <br> (OLS Coef) | Persistence of Stage 2 hypertension 2013-17 <br> (Odds Ratio) | Change in systolic BP 2013-17 (OLS Coef) | $\begin{aligned} & \text { Change in } \\ & \text { systolic } \\ & \text { BP } \\ & \mathbf{2 0 1 3 - 1 7} \\ & \text { (OLS Coef) } \end{aligned}$ | Change in diastolic BP 2013-17 (OLS Coef) |
| Schooling (Ref.: No formal schooling) At least some formal schooling (primary or secondary) | $\begin{gathered} 0.73 \\ {[0.41,1.30]} \end{gathered}$ | $\begin{gathered} -1.20 \\ {[-4.36,1.97]} \end{gathered}$ | $\begin{gathered} 0.92 \\ {[0.55,1.55]} \end{gathered}$ | $\begin{gathered} 2.38 \\ {[-2.83,7.59]} \end{gathered}$ | $\begin{gathered} 1.37 \\ {[0.69,2.74]} \end{gathered}$ | $\begin{gathered} 2.52 \\ {[-5.51,10.6]} \end{gathered}$ | $\begin{gathered} 0.51 \\ {[-2.49,3.51]} \end{gathered}$ | $\begin{gathered} 0.16 \\ {[-1.26,1.58]} \end{gathered}$ |
| Wealth (z-score, based on 14-item asset ow Wealth (z-score) | $\begin{gathered} \text { nership) } \\ 1.20 \\ {[0.96,1.50]} \end{gathered}$ | $\begin{gathered} 0.68 \\ {[-0.73,2.09]} \end{gathered}$ | $\begin{gathered} 1.10 \\ {[0.86,1.40]} \end{gathered}$ | $\begin{gathered} 1.87^{+} \\ {[-0.12,3.85]} \end{gathered}$ | $\begin{gathered} 1.35 \\ {[0.93,1.94]} \end{gathered}$ | $\begin{gathered} 2.14 \\ {[-1.64,5.91]} \end{gathered}$ | $\begin{gathered} 1.20^{+} \\ {[-0.066,2.46]} \end{gathered}$ | $\begin{gathered} 0.35 \\ {[-0.34,1.04]} \end{gathered}$ |
| Wealth (house with metal roof; Ref.: none) Metal roof | $\begin{gathered} 1.39 \\ {[0.91,2.11]} \end{gathered}$ | $\begin{gathered} 1.48 \\ {[-1.34,4.29]} \end{gathered}$ | $\begin{gathered} 1.60^{+} \\ {[0.96,2.65]} \end{gathered}$ | $\begin{gathered} 2.44 \\ {[-2.28,7.16]} \end{gathered}$ | $\begin{gathered} 0.93 \\ {[0.44,1.98]} \end{gathered}$ | $\begin{gathered} 0.053 \\ {[-7.99,8.10]} \end{gathered}$ | $\begin{gathered} 1.99 \\ {[-0.61,4.60]} \end{gathered}$ | $\begin{gathered} 1.02 \\ {[-0.27,2.32]} \end{gathered}$ |
| Grip strength (average both hands) Grip strength | $\begin{gathered} 1.01 \\ {[0.97,1.05]} \end{gathered}$ | $\begin{gathered} 0.046 \\ {[-0.23,0.32]} \end{gathered}$ | $\begin{gathered} 1.02 \\ {[0.96,1.07]} \end{gathered}$ | $\begin{gathered} -0.059 \\ {[-0.50,0.38]} \end{gathered}$ | $\begin{gathered} 1.04 \\ {[0.97,1.12]} \end{gathered}$ | $\begin{gathered} 0.20 \\ {[-0.53,0.94]} \end{gathered}$ | $\begin{gathered} -0.053 \\ {[-0.29,0.19]} \end{gathered}$ | $\begin{gathered} -0.045 \\ {[-0.19,0.10]} \end{gathered}$ |
| Observations | $\approx 625$ | $\approx 620$ | $\approx 435$ | $\approx 410$ | $\approx 190$ | $\approx 175$ | $\approx 1030$ | $\approx 1030$ |

Notes: Tables shows the results of OLS regressions (for change in blood pressure) or logistic regressions (for onset or persistence of hypertension) on the on the predictor variables, controlling additionally for age, gender and region. level. Analyses include all MLSFH-MAC respondents with both 2013 and 2017 BP measurement. Within-person change in BP is calculated as the difference of 2017 BP minus 2013 BP. Outliers in BP change are eliminated as they may reflect measurement errors (outliers are defined as being in the $1^{\text {st }}$ or $99^{\text {th }}$ percentile of the 2013-17 change in BP. $p$-values (robust std. errors): $p<0.10,{ }^{*} p<0.05, * *$ $p<0.01$.


[^0]:    *Assistant Research Professor, Population Studies Center, University of Pennsylvania, Philadelphia, PA 19104, USA; Email: iliana@upenn.edu.
    ${ }^{\dagger}$ Assistant Professor, Department of Sport and Health Sciences, Technical University of Munich, Germany; Email: nikkil.sudharsanan@tum.de
    $\ddagger$ Associate Professor, Department of Mental Health, College of Medicine, Blantyre, Malawi; Email: cbandawe@gmail.com.
    §Frederick J. Warren Professor of Demography, Professor in Sociology, 3718 Locust Walk, University of Pennsylvania, Philadelphia, PA 19104, USA; Email: hpkohler@pop.upenn.edu, Homepage: http://www.ssc.upenn.edu/~hpkohler;

